Genotyping analysis of drug resistance related gene mutations in HIV-1 patients who failed in antiviral therapy in Hubei Province,2017-2018
10.3969/j.issn.1006-2483.2020.03.018
- VernacularTitle:2017-2018年湖北省HIV-1抗病毒治疗失败患者耐药检测结果分析
- Author:
Yake LEI
1
;
Ying DAI
1
;
Kangping ZHOU
1
;
Qili ZENG
1
;
Jun LIU
2
Author Information
1. Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention, Wuhan 430079, China
2. Central office, Qianjiang City Center for Disease Control and Prevention, Qianjiang, Hubei 433199, China
- Publication Type:Journal Article
- Keywords:
AIDS;
HAART;
Drug resistance mutation
- From:
Journal of Public Health and Preventive Medicine
2020;31(3):73-75
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze HIV-1 drug resistance gene mutations in AIDS patients who failed first-line antiviral therapy in Hubei Province from 2017 to 2018, and to provide references for clinical treatment. Methods Plasma samples of HIV patients who had received first-line antiviral treatment for more than 12 months and had a viral load greater than 103 copies / ml were collected in Hubei Province, and drug resistance genotypes were detected. The prevalence and characteristics of drug resistance were analyzed. Results A total of 198 patients were selected, and 182 target gene sequences were successfully detected. The gene subtypes were mainly CRF01_AE, with a total drug resistance rate of 69.23%. The proportion of NRTIs, NNRTIs and PIs resistance mutations was 46.15%, 65.38% and 0.55%, respectively. The occurrence of cross resistance mutations of NRTIs and NNRTIs reached 40.66%. The mutation sites related to NRTIs were mainly M184V and K65R, while the mutation sites related to NNRTIs were mainly V179D, K103N and Y181C. There was only one case of PIs related mutation at the site of M46I. Conclusion HIV-1 genotyping demonstrated a high proportion of drug resistance in the HAART failure population in Hubei Province, and multi-drug resistance occurred frequently. It is necessary to strengthen the monitoring of drug resistance, implement timely adjustments to antiviral treatment programs, and reduce the occurrence and spread of drug-resistant strains.
